Abstract: A cDNA corresponding to the chicken interferon-.gamma. (IFN-.gamma.) gene has been isolated. The invention thus provides avian IFN-.gamma. polypeptides, nucleic acids encoding them, and their recombinant production. The nucleic acids and polypeptides are useful as therapeutic agents and as adjuvants for the treatment of birds.
Type:
Grant
Filed:
April 25, 1997
Date of Patent:
July 4, 2000
Assignee:
Commonwealth Scientific and Industrial Research Organization
Inventors:
John William Lowenthal, Jennifer Joy York, Terri Ellen O'Neil, Stephen Rhodes, Matthew Robert Digby
Abstract: The present invention provides method of increasing the biological activity of KC, gro-.alpha., gro-.beta., and gro-.gamma. proteins, truncated and modified proteins characterized by having biological activity at least 1 log better than the full-length protein, and pharmaceutical compositions containing same.
Type:
Grant
Filed:
March 5, 1996
Date of Patent:
June 27, 2000
Assignee:
SmithKline Beecham Corporation
Inventors:
Louis Martin Pelus, Pradip Kumar Bhatnagar, Andrew Garrison King, Joanna Maria Balcarek
Abstract: The invention relates to nucleotides and amino acid sequences encoding glucagon-like peptide 2 receptors, recombinant host cells transformed with such nucleotides, and methods of using the same in drug screening and related applications.
Type:
Grant
Filed:
April 24, 1997
Date of Patent:
June 20, 2000
Assignee:
Allelix Biopharmaceuticals, Inc.
Inventors:
Donald G. Munroe, Ashwani K. Gupta, Tejal B. Vyas, Kirk McCallum, Ermei Fan
Abstract: Disclosed are novel nucleic acid and peptide compositions comprising latent TGF.beta. binding proteins (LTBPs). Also disclosed are methods of using LTBP-2 and LTBP-3 peptides and the DNA segments which encode them.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
June 13, 2000
Assignee:
The Regents of The University of Michigan
Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin or IL-3 variant. These hIL-3 variants contain amino acid substitutions and may also have amino acid deletions at both the N- and C- termini. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
Type:
Grant
Filed:
November 15, 1995
Date of Patent:
June 13, 2000
Assignee:
G. D. Searle & Co.
Inventors:
S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally co-administered with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
May 9, 2000
Assignee:
G. D. Searle & Co.
Inventors:
S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
Abstract: Disclosed is a genomic DNA encoding a polypeptide capable of inducing the production of interferon-.gamma. by immunocompetent cells. The genomic DNA efficiently expresses the polypeptide with high biological activities of such as inducing the production of interferon-.gamma. by immunocompetent cells, enhancing killer cells' cytotoxicity and inducing killer cells' formation, when introduced into mammalian host cells. The high biological activities of the polypeptide facilitate its uses to treat and/or prevent malignant tumors, viral diseases, bacterial infectious diseases and immune diseases without serious side effects when administered to humans.
Abstract: The present invention is directed to isolated nucleic acid molecules encoding a voltage gated sodium channel of a peripheral nerve cell, as well as to the isolated voltage gated sodium channels of a peripheral nerve cell encoded thereby. Methods for increasing or decreasing the expression of functional voltage gated sodium channels in host cells are also provided, as well as methods using the sodium channels. Also provided is a method for isolating other voltage gated sodium channels.
Type:
Grant
Filed:
February 9, 1996
Date of Patent:
May 9, 2000
Assignee:
Cornell Research Foundation, Inc.
Inventors:
Jose L. Walewski, Esperanza Recio-Pinto
Abstract: The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF), cytokine, lymphokine, interleukin, hematopoietic growth factor or IL-3 variant. The invention also relates to pharmaceutical compositions containing the fusion molecules and methods for using them.
Type:
Grant
Filed:
February 4, 1994
Date of Patent:
May 2, 2000
Assignee:
G. D. Searle
Inventors:
S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John Patrick McKearn, Peter O. Olins, Kumnan Paik, John Warren Thomas
Abstract: Provided are methods of making preparations of recombinant soluble Complement Receptor type 1 (sCR1) defined with respect to the distribution of sCR1 glycoforms and therapeutic methods using them. The preparations are suitable for treatment of allograft or xenograft rejection, diseases involving inflammation or inappropriate complement activation, and thrombotic or shock state conditions. Preferred methods employ sCR1 glycoforms that are sialylated, have a pI of .ltoreq.5.1, or have a sialic acid: mannose molar ratio of .gtoreq.0.25.
Type:
Grant
Filed:
November 5, 1998
Date of Patent:
May 2, 2000
Assignee:
Avant Immunotherapeutics, Inc.
Inventors:
Henry C. Marsh, Jr., Richard A. G. Smith, Chang-Jing Grace Yeh, John Lifter, Anne Mary Freeman, Michael L. Gosselin
Abstract: The present invention relates to a recombinant glucagonlike peptide-1 (GLP-1) receptor having the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:3, wherein the receptor polypeptide binds GLP-1 with a Kd of less than 100 nM.
Abstract: The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a.119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
April 18, 2000
Assignee:
G. D. Searle & Co.
Inventors:
S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan Michael Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
Abstract: DNA encoding modified, secretable erythropoietin proteins whose ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant erythropoietin and to methods of modifying or altering the regulating activity of a secretable erythropoietin and using modified secretable erythropoietin proteins.
Abstract: The mammalian TGF-.beta. type II receptor has been cloned. Recombinant TGF-.beta.-binding receptor polypeptides are useful to alter the binding of TGF-.beta. to its receptors and to modulate the effects of TGF-.beta. in vivo.
Type:
Grant
Filed:
May 23, 1995
Date of Patent:
April 4, 2000
Assignee:
Whitehead Institute for Biomedical Research
Inventors:
Herbert Y. Lin, Xiao-Fan Wang, Robert A. Weinberg, Harvey F. Lodish
Abstract: The invention provides new variants of recombinant human interferon-.gamma. (rhIFN-.gamma.), vectors and host cells for their production, and therapeutic methods employing them. The variants are characterized by the substitution of one or more pairs of amino acids selected from Glu.sup.8 -Ser.sup.70, Ala.sup.18 -His.sup.112, Lys.sup.81 Leu.sup.121, and Gln.sup.49 -Leu.sup.96 by pairs of Cys residues, and optionally by the deletion of from one to ten amino acid residues from C-terminus of the native IFN-.gamma. sequence. The variants of the invention exhibit greater thermal stability and no loss of biological activity as compared to native-sequence rhIFN-.gamma..
Type:
Grant
Filed:
May 11, 1998
Date of Patent:
April 4, 2000
Assignee:
Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E. V.
Inventors:
Gero Waschutza, Volkhart Li, Bernd Otto
Abstract: A method is described for using interferon in the treatment of human patients afflicted with fibromyalgia to alleviate one or more symptoms associated with that disease state. Fibromyalgia positive patients treated buccally, sublingually or by oral ingestion administration of low doses of interferon enjoy a reduction in clinical symptoms of the disease.
Abstract: The invention provides modified mammalian transforming growth factor (TGF)-.beta. type I receptors (T.beta.R-I) which substantially retain the ability of native T.beta.R-I to transduce signals for matrix protein production but which have a diminished capacity to transduce growth-inhibitory signals. The receptors of the invention are characterized by the replacement or deletion of one or more residues in the juxtamembrane region between the transmembrane and GS domains, e.g., the residues corresponding to Ser.sup.172 or Thr.sup.176 of hT.beta.R-I. The invention also provides recombinant expression systems for production of the modified receptors and assays using them for the identification of antiproliferative agents.
Abstract: The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins, hematopoietic growth factors or IL-3 variants.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
February 29, 2000
Assignee:
G. D. Searle & Company
Inventors:
S. Christopher Bauer, Mark Allen Abrams, Sarah Ruth Braford-Goldberg, Maire Helena Caparon, Alan M. Easton, Barbara Kure Klein, John P. McKearn, Peter O. Olins, Kumnan Paik, John W. Thomas
Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in hum tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as wel as in sporadic colorectal cancer patents. APC is expressed in most normal tissue. These results suggest that APC is a tumor suppressor.
Type:
Grant
Filed:
October 4, 1996
Date of Patent:
May 23, 2000
Assignees:
The Johns Hopkins University, The University of Utah, Zeneca, Cancer Institute
Inventors:
Bert Vogelstein, Kenneth W. Kinzler, Hans Albertson, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Alexander Fred Markham, Yusuke Nakamura, Andrew Thliveris, Raymond White
Abstract: Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
Type:
Grant
Filed:
August 31, 1998
Date of Patent:
June 27, 2000
Assignee:
Immunex Corporation
Inventors:
Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann